Latest Articles
FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma - Targeted Oncology
FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma Targeted Oncology
Published: Nov. 12, 2025, 7:08 p.m.
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? - ts2.tech
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? ts2.tech
Published: Nov. 3, 2025, 2:12 p.m.
Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: Oct. 27, 2025, 3:49 p.m.
Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer - Targeted Oncology
Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer Targeted Oncology
Published: Oct. 22, 2025, 6:21 p.m.
Endometrial Cancer: Dostarlimab/Chemo Improves OS in Frontline RUBY Trial - Targeted Oncology
Endometrial Cancer: Dostarlimab/Chemo Improves OS in Frontline RUBY Trial Targeted Oncology
Published: Oct. 22, 2025, 5:11 p.m.
Poll Results Highlight Gynecologic Oncology Abstracts to Watch Ahead of ESMO 2025 - OncLive
Poll Results Highlight Gynecologic Oncology Abstracts to Watch Ahead of ESMO 2025 OncLive
Published: Oct. 10, 2025, 12:07 p.m.
Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775 - BioSpace
Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775 BioSpace
Published: Oct. 3, 2025, 10:53 a.m.
Eisai Highlights Breadth of Oncology Research at ESMO 2025 - JCN Newswire
Eisai Highlights Breadth of Oncology Research at ESMO 2025 JCN Newswire
Published: Oct. 3, 2025, 9:01 a.m.
Eisai Highlights Breadth of Oncology Research at ESMO 2025 - ACN Newswire - ACN Newswire
Eisai Highlights Breadth of Oncology Research at ESMO 2025 - ACN Newswire ACN Newswire
Published: Oct. 3, 2025, 9:01 a.m.
Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775 - Morningstar
Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775 Morningstar
Published: Oct. 2, 2025, 12:08 p.m.
Link copied to clipboard!